BR112022003598A2 - Métodos para tratamento da doença cln2 em indivíduos pediátricos - Google Patents
Métodos para tratamento da doença cln2 em indivíduos pediátricosInfo
- Publication number
- BR112022003598A2 BR112022003598A2 BR112022003598A BR112022003598A BR112022003598A2 BR 112022003598 A2 BR112022003598 A2 BR 112022003598A2 BR 112022003598 A BR112022003598 A BR 112022003598A BR 112022003598 A BR112022003598 A BR 112022003598A BR 112022003598 A2 BR112022003598 A2 BR 112022003598A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- subject
- disease
- cln2 disease
- cln2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
métodos para tratamento da doença cln2 em indivíduos pediátricos. a presente invenção refere-se a métodos de tratamento da doença lipofuscinose ceroide neuronal (cln2) em um indivíduo com menos de 3 anos de idade. em modalidades exemplificativas, o método compreende administrar ao indivíduo uma formulação que compreende tripeptidil peptidase-1 humana recombinante (rhtpp1) em uma quantidade eficaz para tratar a doença cln2 no indivíduo. também são fornecidos métodos para retardar o início da doença cln2, ou um sintoma da mesma, em um indivíduo com menos de 3 anos de idade. em modalidades exemplificativas, o método compreende administrar ao indivíduo uma formulação que compreende tripeptidil peptidase-1 humana recombinante (rhtpp1) em uma quantidade eficaz para retardar o início da doença ou sintoma de cln2 no indivíduo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962893535P | 2019-08-29 | 2019-08-29 | |
PCT/US2020/048704 WO2021042020A1 (en) | 2019-08-29 | 2020-08-31 | Methods for treating cln2 disease in pediatric subjects |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022003598A2 true BR112022003598A2 (pt) | 2022-05-24 |
Family
ID=72470612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022003598A BR112022003598A2 (pt) | 2019-08-29 | 2020-08-31 | Métodos para tratamento da doença cln2 em indivíduos pediátricos |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220273775A1 (pt) |
EP (1) | EP4021575A1 (pt) |
JP (1) | JP2022546042A (pt) |
KR (1) | KR20220054375A (pt) |
CN (1) | CN114828960A (pt) |
AR (1) | AR119871A1 (pt) |
AU (1) | AU2020336984A1 (pt) |
BR (1) | BR112022003598A2 (pt) |
CA (1) | CA3152521A1 (pt) |
CL (1) | CL2022000496A1 (pt) |
HR (1) | HRP20220370A1 (pt) |
IL (1) | IL290763A (pt) |
MX (1) | MX2022002451A (pt) |
TW (1) | TW202122106A (pt) |
WO (1) | WO2021042020A1 (pt) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6302685B1 (en) | 1997-09-16 | 2001-10-16 | University Of Medicine And Dentistry Of New Jersey | Human lysosomal protein and methods of its use |
US20020006400A1 (en) * | 2000-05-11 | 2002-01-17 | Peter Lobel | Recombinant human CLN2 protein and methods of its production and use |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
US20140377244A1 (en) | 2011-12-23 | 2014-12-25 | Shire Human Genetic Therapies, Inc. | Stable formulations for cns delivery of arylsulfatase a |
TWI752907B (zh) * | 2015-05-08 | 2022-01-21 | 美商拜奧馬林製藥公司 | 用於治療cln2疾病之tpp1調配物及方法 |
CN108601771B (zh) * | 2015-10-23 | 2023-02-21 | 衣阿华大学研究基金会 | 使用基因疗法以推迟疾病发生和发展同时提供认知保护来治疗神经变性疾病的方法 |
MX2021005517A (es) * | 2018-11-14 | 2021-06-18 | Regenxbio Inc | Terapia genica para lipofuscinosis neuronal ceroidea. |
-
2020
- 2020-08-31 JP JP2022513165A patent/JP2022546042A/ja active Pending
- 2020-08-31 CN CN202080068971.3A patent/CN114828960A/zh active Pending
- 2020-08-31 BR BR112022003598A patent/BR112022003598A2/pt unknown
- 2020-08-31 AR ARP200102442A patent/AR119871A1/es unknown
- 2020-08-31 US US17/638,029 patent/US20220273775A1/en active Pending
- 2020-08-31 AU AU2020336984A patent/AU2020336984A1/en active Pending
- 2020-08-31 MX MX2022002451A patent/MX2022002451A/es unknown
- 2020-08-31 EP EP20771408.0A patent/EP4021575A1/en active Pending
- 2020-08-31 HR HRP20220370AA patent/HRP20220370A1/hr unknown
- 2020-08-31 WO PCT/US2020/048704 patent/WO2021042020A1/en unknown
- 2020-08-31 KR KR1020227010387A patent/KR20220054375A/ko unknown
- 2020-08-31 TW TW109129724A patent/TW202122106A/zh unknown
- 2020-08-31 CA CA3152521A patent/CA3152521A1/en active Pending
-
2022
- 2022-02-21 IL IL290763A patent/IL290763A/en unknown
- 2022-02-28 CL CL2022000496A patent/CL2022000496A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
HRP20220370A1 (hr) | 2022-09-16 |
EP4021575A1 (en) | 2022-07-06 |
CL2022000496A1 (es) | 2022-10-21 |
MX2022002451A (es) | 2022-06-02 |
US20220273775A1 (en) | 2022-09-01 |
AR119871A1 (es) | 2022-01-19 |
CN114828960A (zh) | 2022-07-29 |
WO2021042020A1 (en) | 2021-03-04 |
TW202122106A (zh) | 2021-06-16 |
IL290763A (en) | 2022-04-01 |
KR20220054375A (ko) | 2022-05-02 |
CA3152521A1 (en) | 2021-03-04 |
AU2020336984A1 (en) | 2022-03-10 |
JP2022546042A (ja) | 2022-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Nimma et al. | Holistic healing through herbs: Effectiveness of Aloe vera on post extraction socket healing | |
Bolouri et al. | Preventing and therapeutic effect of propolis in radiotherapy induced mucositis of head and neck cancers: a triple-blind, randomized, placebo-controlled trial | |
Zykova et al. | Macrophage stimulating agent soluble yeast β‐1, 3/1, 6‐glucan as a topical treatment of diabetic foot and leg ulcers: A randomized, double blind, placebo‐controlled phase II study | |
BR112018016001A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
BR112017023805A2 (pt) | formulações de tpp1 e métodos para o tratamento de doença lcn2 | |
Micheli et al. | Bacopa monnieri as augmentation therapy in the treatment of anhedonia, preclinical and clinical evaluation | |
Jeon et al. | Effect of acupuncture on diabetic peripheral neuropathy: an uncontrolled preliminary study from Korea | |
Wilkerson et al. | Poly‐L‐lactic acid for the Improvement of photodamage and rhytids of the décolletage | |
Izumi et al. | Efficacy of an emollient containing diethylene glycol/dilinoleic acid copolymer for the treatment of dry skin and pruritus in patients with senile xerosis | |
Paterson et al. | A randomized, double-blind, placebo-controlled, sequential parallel study of CERC-301 in the adjunctive treatment of subjects with severe depression and recent active suicidal ideation despite antidepressant treatment | |
BR112022007595A2 (pt) | Métodos para tratar doença de alzheimer | |
Wang et al. | Inhibition of extracellular signal-regulated kinase/calpain-2 pathway reduces neuroinflammation and necroptosis after cerebral ischemia-reperfusion injury in a rat model of cardiac arrest | |
BR112023001143A2 (pt) | Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo | |
Ahmed et al. | Efficacy of clarithromycin in pityriasis rosea | |
BR112022003598A2 (pt) | Métodos para tratamento da doença cln2 em indivíduos pediátricos | |
Xiao et al. | Lithium chloride ameliorated spatial cognitive impairment through activating mTOR phosphorylation and inhibiting excessive autophagy in the repeated cerebral ischemia‑reperfusion mouse model | |
Xue et al. | Analgesic mechanism of electroacupuncture in a rat L5 spinal nerve ligation model | |
BR112022027124A2 (pt) | Formulações para promover a hidratação e métodos de uso das mesmas | |
Hirabayashi et al. | Analgesic effect of mineral cream containing natural spa minerals for use on the skin | |
EP3534874B1 (en) | Cosmetic method | |
Łopuszyńska et al. | Anti-aging properties of metformin | |
Ghuman et al. | Ketorolac and morphine for analgesia in acute renal colic: Is this combination more effective than monotherapy? | |
Bassi et al. | Inflammatory morphea presenting as a hemifacial acquired port-wine stain | |
Nakamura et al. | Narrowband UVB-induced iatrogenic polymorphous light eruption: A case and suggestions to overcome this rare complication | |
Yuan et al. | Transcranial direct current stimulation in patients with Alzheimer’s disease: challenges and responses |